Series A+ · Biotech
Third Arc Bio: Series A+
Develops novel multifunctional antibodies for oncology and immunology & inflammation indications
Funding history
Series A+ · This round$52M
Develops novel multifunctional antibodies for oncology and immunology & inflammation indications